Core Viewpoint - Avalon GloboCare Corp. has successfully closed a private placement, raising approximately $3.25 million, with potential additional proceeds of up to $6.5 million from warrants [1][3]. Group 1: Financial Details - The private placement involved the issuance and sale of 6,372,550 shares of common stock at a purchase price of $0.51 per share, along with Series A-1 and A-2 warrants [1]. - The gross proceeds from the offering were approximately $3.25 million before deducting fees and expenses, with potential additional gross proceeds of approximately $6.5 million if the warrants are fully exercised [3]. - The net proceeds from the offering will be used for debt repayment, working capital, and general corporate purposes [3]. Group 2: Warrants Information - Series A-1 warrants will expire five years from stockholder approval, while Series A-2 warrants will expire eighteen months from stockholder approval [1]. - The warrants have an exercise price of $0.51 per share and will be exercisable upon stockholder approval [1]. Group 3: Company Overview - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and generative AI publishing and software [1]. - The company is advancing AI systems through its subsidiary, Avalon Quantum AI LLC, and is expanding its intellectual property in cellular therapy and generative AI [6]. - Avalon is also marketing the KetoAir™ breathalyzer device, registered as a Class I medical device with the FDA, and plans to pursue additional diagnostic applications [6].

As filed with the Securities and Exchange Commission on February 27, 2026. Registration No. 333-292284 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MiniMed Group, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3841 33-3985981 (I.R.S. Employer Identification N ...

Key Takeaways SOLV posted Q4 adjusted EPS of $1.57 on $1.99B revenue, topping consensus estimates.SOLV saw organic growth across MedSurg, Dental, and HIS, led by infection prevention and restoratives.SOLV's gross margin fell 270 bps, while adjusted operating income declined 5.9% year over year.Solventum (SOLV) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.57, which beat the Zacks Consensus Estimate of $1.50 by 4.7%. The bottom line improved 11.3% year over year.GAAP EPS in the quarter ...

A month has gone by since the last earnings report for Conmed (CNMD) . Shares have added about 22.9% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Conmed due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for CONMED Corporation before we dive into how investors and analysts have reacted as of late.CONMED Posts Q4 Earnings and Rev ...

As filed with the Securities and Exchange Commission on February 27, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MODULAR MEDICAL INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 3841 87-0620495 (I.R.S. Employer Identification Number) 10470 Thornmint Road ...

Group 1 - UFP Technologies, Inc. will participate in the Raymond James 47th Annual Institutional Investors Conference in Orlando, Florida from March 1-4, 2026, with a presentation scheduled for March 3 at 2:50 PM [1] - The company specializes in contract development and manufacturing of single-use and single-patient medical devices, serving as a crucial link in the medical device supply chain [2] - UFP Technologies is a valued outsourcing partner for leading medical device manufacturers, providing components for various applications including minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants [2]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks St ...

Key Takeaways XRAY rose nearly 7.8% pre-market despite a Q4 earnings miss and margin contraction.DENTSPLY SIRONA posted 6.2% Q4 revenue growth, beating estimates on sales recovery.XRAY unveiled a $120M cost-saving restructuring and will halt dividends to cut debt.DENTSPLY SIRONA Inc. (XRAY) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 27 cents, up 3.8% year over year. The bottom line missed the Zacks Consensus Estimate by 3.6%.GAAP loss per share in the quarter under review was 74 cents ...

Treace Medical Concepts (NasdaqGS:TMCI) Q4 2025 Earnings call February 27, 2026 08:00 AM ET Company ParticipantsJohn Treace - CEO, Founder, and Chairman of the BoardMark Hair - CFORichard Newitter - Managing DirectorRick Wise - Managing DirectorTripp Taylor - VP of Investor RelationsConference Call ParticipantsBen Haynor - Senior Research AnalystDanielle Antalffy - Senior AnalystRyan Zimmerman - Managing Director and Medical Technology AnalystNone - AnalystOperatorGood day. Thank you for standing by. Welcom ...

Treace Medical Concepts (NasdaqGS:TMCI) Q4 2025 Earnings call February 27, 2026 08:00 AM ET Speaker5Good day. Thank you for standing by. Welcome to the Treace Medical Concepts fourth quarter and full year 2025 earnings conference call. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. After the speaker's presentation, there will be a question-and-answer session. To ask a question, please press star one one on your telephone and wait for yo ...